文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌新辅助化疗后孤立淋巴结残留与持续肌层浸润性疾病的结局差异:国际多中心研究

Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An International Multi-Institutional Study Comparing Isolated Nodal Disease vs Persistent Muscle-Invasive Disease.
PubMed 文献 · Urology · 2025-04-16

回顾性分析174例新辅助化疗后行根治性膀胱切除术患者,比较孤立淋巴结残留(n=35)与持续肌层浸润/局部晚期无淋巴结受累(n=139)的结局。

要点

  • 新辅助化疗后孤立淋巴结残留者复发风险高于持续肌层浸润无淋巴结受累者。
  • 两组疾病特异性死亡率和生存无显著差异。
  • 变异组织学(36%病例)未影响结局。

核心结论

  • 新辅助化疗后孤立淋巴结残留患者复发风险更高,但未转化为生存差异。
  • 建议对孤立残留淋巴结病变患者考虑风险适配监测及额外治疗干预。

研究设计与样本

  • 回顾性分析2010至2023年美国与欧洲学术中心174例新辅助化疗后根治性膀胱切除术患者。
  • 分为孤立淋巴结病变伴完全局部缓解组(n=35)与持续肌层浸润或局部晚期无淋巴结受累组(n=139)。
  • 中位随访27.0个月(四分位距9.0-60.0)。

主要发现

  • 生存分析显示两组疾病特异性死亡率无显著差异(HR 1.03,95%CI 0.48-2.20,P=0.947)。
  • 变异组织学见于36%病例,未影响结局。

临床怎么用

  • 对新辅助化疗后孤立淋巴结残留患者应加强复发监测。
  • 可考虑对孤立残留淋巴结病变患者追加治疗干预。

局限性

  • 回顾性研究设计。
  • 样本量有限(174例),孤立淋巴结组仅35例。
  • 中位随访27.0个月相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate clinical outcomes based on patterns of residual disease in patients undergoing cystectomy after neoadjuvant chemotherapy (NAC), focusing on those with residual tumor only in lymph nodes. METHODS: We retrospectively analyzed 174 patients who underwent post-NAC radical cystectomy between 2010 and 2023 at academic centers from the United States and Europe. Patients were stratified into two groups: those with isolated lymph node disease despite complete local response (n=35) and those with persistent muscle-invasive or locally advanced disease without lymph node involvement (n=139). Primary outcomes included recurrence, disease-specific mortality (DSM), and survival. Median follow-up was 27.0months (interquartile range: 9.0-60.0). RESULTS: Recurrence occurred in 33% of patients, with higher risk in patients with residual disease only in lymph nodes compared to those with persistent disease in the bladder and negative lymph nodes (adjusted OR: 0.43, 95% CI: 0.20-0.95, P=.036). DSM was 24%, with no significant difference between groups (adjusted OR: 0.70, 95% CI: 0.29-1.64, P=.407). Disease-related events occurred in 41% of patients, with lower risk in the group with residual disease in the bladder (adjusted OR: 0.46, 95% CI: 0.21-0.99, P=.048). Survival analyses showed no significant differences in DSM between groups (HR: 1.03, 95% CI: 0.48-2.20, P=0.947). Variant histology (present in 36% of cases) did not influence outcomes. CONCLUSION: Patients with isolated lymph node disease, despite complete local response after NAC, demonstrate higher recurrence risk compared to those with persistent muscle-invasive disease, although this does not translate into survival differences. These findings suggest the need for risk-adapted surveillance strategies and consideration of additional therapeutic interventions in patients with isolated residual nodal disease.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Acosta AM, Saad M, Chaux A, et al. Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An International Multi-Institutional Study Comparing Isolated Nodal Disease vs Persistent Muscle-Invasive Disease. Urology. 2025. PMID: 40250715. doi:10.1016/j.urology.2025.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。